TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* An individual with an adrenal neoplasm less than 5 cm in size with biochemically confirmed evidence of hypercortisolism (2 out of 3: dexamethasone suppression test (DST) \>3 mcgl/dL, elevated urine free cortisol, and/or morning adrenocorticotropic hormone (ACTH) \<2.2 pmol/l) without overt clinical signs and symptoms.~* Age greater than or equal to 18 years.~* Adults must be able to understand and sign the informed consent document.~* Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice.~EXCLUSION CRITERIA:~* Biochemically and/or radiologically confirmed pheochromocytoma, hyperaldosteronism, or adrenocortical carcinoma.~* Nonfunctioning adrenal neoplasm.~* Pre-existing cancers and/or metastatic disease to the adrenal glands.~* Pregnancy and/or lactation.~* Lack of metabolic complications.~* Imaging features worrisome for malignancy (heterogeneous tumor, presence of calcifications, necrosis, \>10 Hounsfield units on an unenhanced computed tomography (CT) scan, and delayed washout of contrast).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Operative Arm (Type: OTHER): operative arm
- Delayed Operative Arm (Type: OTHER): delayed operative arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient aged \> 18 years old~* patient with metastatic non-small cell lung cancer with marketing authorisation criteria for immunotherapy~* preserved overall condition (Performans Status 1)~* signed informed consent~* patient with healthcare insurance~Non Inclusion Criteria:~* patient with oxygen therapy or invasive ventilation~* patient unable to perform a slow vital capacity~* systemic corticosteroid therapy more than 10 mg per day of prednisone equivalent~* previous treatment with immunotherapy~* dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)~* Patient deprived of liberty by judicial or administrative decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VOC analysis (Type: EXPERIMENTAL): VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe Traumatic brain injury monitored with ICP, PtiO2 and cerebral microdialysis~* And ICP\> 20 mm Hg needing osmotherapy~* And approval of the next of kind~Exclusion Criteria:~* Bilateral fixed dilated pupils~* Contra-indication to multimodal neuromonitoring~* Previous CNS disease~* Contra-indication to HS (cardiac insufficiency,...)~* Natremia \> 155 mmol/L or osmolarity \> 320 mOsm/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mannitol (Type: ACTIVE_COMPARATOR): None
- Hypertonic saline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib-induced Hand- Foot Skin Reaction Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving sorafenib as monotherapy or in combination if other agents are not known to cause HFSR.~* Subjects must be 18 years or older.~* Patients must provide written informed consent to participate in the study.~* Women of childbearing potential and men must be willing to use an effective method of contraception while participating in this study and for at least two weeks after completing treatment in the study.~* Women in this study need to have a negative urine pregnancy test before starting study medications.~Exclusion Criteria:~* Patients simultaneously taking another anti-cancer agent or combination of anti-cancer agents known to cause hand foot syndrome (pegylated doxorubicin, 5-fluorouracil, cytarabine).~* Patients with an active dermatological condition due to previous chemotherapy or biologic therapy affecting the hands.~* Patients with pre-existing dermatological condition affecting the hands or feet.~* Women who have a positive pregnancy test or are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- urea 40% cream (Type: EXPERIMENTAL): None
- fluocinonide 0.05% cream (Type: EXPERIMENTAL): None
- tazarotene 0.1% cream (Type: EXPERIMENTAL): None
- bland emollient cream (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Freeman-Sheldon syndrome,~* Sheldon-Hall syndrome,~* Distal arthrogryposis type 1, or~* distal arthrogryposis type 3~* Deceased probands with enough clinical information available to satisfy study requirements~* Probands who participated in a prior Freeman-Sheldon Research Group (FSRG)-study are automatically accepted, since their diagnoses have been confirmed by FSRG clinical faculty.~* Probands with a reported qualifying diagnosis, who have not participated in a prior FSRG-study, will be required to complete the complete a survey from a prior study and provide photographs and any requested medical records to confirm their diagnoses.~* Family members and other close contacts may enrol, so long as they have either resided with or had substantial and prolonged contact with a proband, who has an FSRG-verified qualifying diagnosis. Investigators will make the final decision on a case-by-case basis, based on information provided.~Exclusion Criteria:~* Patients with other anomalies, not having one of the above syndromes, will not be accepted.~* Deceased probands will not be accepted for analysis, without enough clinical data available to satisfy study data collection requirements.~* Patients or parents of minor children not willing to give consent will not be included.~* Family members or other contacts that neither resided with nor had substantial and prolonged contact with the proband.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proband Group (Type: None): Patients identified with FSS or a related condition
- Family Group (Type: None): Persons who are genetically or legally related to a person with FSS or related condition
- Other Affected Individuals Group (Type: None): Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of TBI and a GCS 7-12~* Only isolated TBI~* CT~* Pre-Trauma Karnofsky-Index = 100~* Age 18-60 years~* Male and female patients~* Time to needle for study medication within 6 hours after injury~* Patient is not pregnant or lactating during the trial and is not of childbearing potential~* Patient was able to speak, read and write in a pre-defined study language before the accident.~* Reasonable expectation of completion of outcome measures at follow-up~* Written informed consent~Exclusion Criteria:~* Evidence of pre-existing major health problems~* Any neurological or non-neurological condition independent from TBI that might influence the functional outcome or other efficacy outcome measures~* Injury of writing hand influencing cognitive or other outcome measures~* Clear clinical signs of intoxication influencing the evaluation~* Major drug dependency including alcohol~* Chronic treatment with steroids, Ca2+-channel blockers or major anticoagulants~* Penetrating high-velocity missile head trauma~* Stab wound trauma into the brain~* Patients with spinal cord injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 0.9% NaCl, saline (Type: PLACEBO_COMPARATOR): None
- Cerebrolysin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Confocal Endomicroscopy for Biliary Strictures -Phase I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-ERCP: Age above 18; imaging consistent with stenosis/mass of the hilum/extra-hepatic bile duct with abnormal liver chemistry, or painless jaundice referred for ERCP.~* Evidence of biliary obstruction as defined by elevated direct bilirubin (\> 1.5ULN) and dilation of the common or hepatic ducts \> 8mm) on imaging studies.~Exclusion Criteria:~* Unwilling/unable to consent.~* Definite pancreatic mass on CT/MR.~* Allergy to Fluorescein.~* Pregnancy (patient who could be pregnant will undergo pregnancy testing as per routine care)~* Indwelling metal biliary stent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1. To compare confocal image characteristics of benign vs. malignant biliary strictures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Steroid-Induced Osteoporosis in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic inflammatory disease or transplant recipient, currently on steroid therapy at supraphysiologic dose (greater than hydrocortisone equivalent of 15 mg/m2/day) for more than 6 months~* Bone age less then 14 years in females, 16 years in males, to correspond to \< 90% of peak BMD~And~* Presence of glucocorticoid induced bone disease defined by:~* Presence of at least one atraumatic fracture (defined as fracture that occurs during activities of daily living, without a fall), or a vertebral fracture, OR~* AP lumbar spine BMD (determined by DEXA) of more than 2 or more SD below the mean lumbar BMD for a healthy child of similar stature (height age). OR~* A low trauma fracture (suspicious fracture - defined as a fracture the occurs with a fall from standing height or below, and not during a high velocity activity) and AP spine BMD 1.5 or more SD below the mean for height age, OR~* Recent loss of BMD of greater then 3% over a 6 month or greater interval at any one of the following sites, lumbar spine, total hip or whole body (excluding head). OR~* Recent increase in BMD of less then 3% over a 12 month period at all of the three sites listed above.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 15 years and older in Colorado and 19 years and older in Nebraska. A waiver of parental consent is planned for individuals 15-17 in accordance with Colorado law which allows minors to consent for treatment for sexually transmitted infections, including HIV.~* Reactive HIV-1 on an approved fourth generation HIV-1 antibody/antigen test within 72 hours~* Any primary language with access to an interpreter by phone is included.~Exclusion Criteria:~* Pregnancy or intention to become pregnant in the next two years after enrollment~* Symptomatic acute HIV (with fever, rash, influenza-like symptoms)~* Creatinine clearance \<30 mL/min by Cockcroft-Gault equation. (Therapy initiated will be terminated promptly in individuals who are found to have creatinine clearance \<30 mL/min)~* Prior history of known HIV diagnosis~* Negative confirmatory HIV differentiation assays (therapy initiated will be terminated in individuals with negative tests and excluded from the primary analysis)~* Allergy to bictegravir, emtricitabine or tenofovir alafenamide~* Signs or symptoms of opportunistic infection with cryptococcal meningitis, tuberculosis or other infection that requires delay of initiation of antiretroviral therapy (up to the discretion of the site PI)~* Vulnerable populations including prisoners and individuals without decision making capacity~* Concommitant use of medications that are contraindicated with bictegravir, emtricitabine and tenofovir alafenamide including adefovir, carbamazepine, cladribine, dofetilide, fosphenytoin-phenytoin, oxcarbazepine, phenobarbital, primidone, rifampin, rifabutin, rifapentine, St. John's Wort, tipranavir

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Rapid Start Group (Type: ACTIVE_COMPARATOR): Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
- Arm B: Standard Group (Type: PLACEBO_COMPARATOR): Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between the age of 23 to 70 years old at screening, inclusive~* GHD subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II (2007).~* No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product.~* The IGF-I level at screening ≤-1 SDS of the age and sex normal ranges according to the central laboratory measurements~* Subjects who are on a stable diet and exercise regime and do not have plans to modify their diet or exercise for at least 12 months~* Subject had a DXA screening and the results are interpretable according to the study plan.~Exclusion Criteria:~* Women who are pregnant or breast-feeding (at least 6 months delay from childbirth or lactation)~* Evidence of growth benign intracranial tumor within the last 12 months (determined by comparing a previous MRI to a new one obtained no more than 6 months prior to study entry to clarify dynamics of growth).~* History of any cancer. Exceptions to this exclusion criterion include resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision. Patients with GHD attributed to treatment of intracranial malignant lesions in childhood or adulthood (or, tumors) or leukemia may also be enrolled into the study provided that a recurrence-free survival period of at least 5 years is well documented in the study record.~* Signs of intracranial hypertension at screening~* Heart insufficiency, NYHA class \> 2 (Appendix B)~* History of overt diabetes mellitus (including currently treated, well-controlled DM) defined according to the American Diabetes Association (ADA) Criteriaa. A history of gestational diabetes, resolved after childbirth, is not exclusionary.~* History of Acromegaly

- Gender: ALL
- Minimum Age: 23 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MOD-4023 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute STEMI with persistent ST-segment elevation or recent left bundle-branch block with a symptom onset to reperfusion time of 12 hours or less.~2. Angiographic criteria included a proximal-mid coronary artery occlusion (TIMI coronary flow grade 0 or 1) or, impaired coronary flow (TIMI flow grade 2, slow but complete filling) in the presence of definite angiographic evidence of large thrombus (TIMI grade ≥2) in left anterior descending (LAD) coronary artery.~Exclusion Criteria:~1. Rescue PCI after thrombolytic therapy.~2. Need for emergency coronary artery bypass grafting.~3. Presence of cardiogenic shock.~4. Life expectancy of \< 6 months.~5. Inability to provide informed consent.~6. Contraindications for the use of thrombolysis, including active internal bleeding, history of intracranial haemorrhage or ischaemic stroke within 6 months, recent major surgery or trauma, severe uncontrolled hypertension, thrombocytopenia and severe liver or kidney failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): intracoronary infusion with saline
- reteplase 9mg (Type: EXPERIMENTAL): intracoronary infusion with reteplase 9mg
- reteplase 18mg (Type: EXPERIMENTAL): intracoronary infusion with reteplase 18mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Post-traumatic Stress Among the Nearest Relatives of Brain-dead Organ Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* must be one of the following: person-of-trust previously designated by the deceased, a spouse, sibling, parent, or child of the deceased~Exclusion Criteria:~* refusal to participate~* does not speak French~* deaf/mute~* adult, but under guardianship

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reference (Type: None): Nearest relatives of brain-dead patients who donated organs
- Opposition (Type: None): Nearest relatives of brain-dead patients opposed to organ donation
- Medical/Legal (Type: None): Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* proven echographic cholecystitis~Exclusion Criteria:~* pregnancy~* immunosuppression~* severe sepsis~* perforated cholecystitis~* peritonitis~* cholangitis~* acute pancreatitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Delayed (Type: ACTIVE_COMPARATOR): Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
- Early (Type: EXPERIMENTAL): Laparoscopic cholecystectomy performed directly after the initial diagnosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues